Psychopharmacological Treatment of Obsessive-Compulsive Disorder Comorbid With Body Dysmorphic Disorder and Pathological Gambling Disorder
Considering PGD, specifically, one report, by Grant et al.6 emphasizes that modulation of glutamate by N-acetylcistein might be of crucial importance in reward-seeking behavior in PGD. The first basic science report of a memantine antagonism effect on glutamate was published in 1991 by Erdo et al.7 on cortical cell cultures, with the most recent spectroscopic study of effects of memantine on glutamate and glutamine concentrations in prefrontal cortex by van Wageningen et al.8
Furthermore, an open-label clinical study was conducted with memantine, showing its positive effects on OCD symptoms.9 Our patient, “Mr. N,” was a 23-year-old university student who was referred to us because of SRI-resistant OCD. Severe OCD and BDD were diagnosed at initial examination, with a YBOCS score 26 and initial YBOCS-BDD score of 30. Mr. N spent about 6 hours/day in obsessions and compulsive ritualistic behavior. The rituals included “ritual for ears,” which consisted of checking his ears on a bathroom mirror three times in a row. Before going to sleep, he checked his face twice in the mirror, then went twice to the bathroom and once outside to the street. If somebody interrupted him during a meal, he had to go to check his appearance in the bathroom mirror. When getting dressed, he avoided touching a wall; if he did touch it, he had to remove his clothes. When he heard the word “pressure,” he was obliged to leave the apartment. He called various parts of the apartment the “territory” (the living room, corridor, mirror, being separate territories). Nobody could interrupt him when crossing from one territory to another. Treatment with the SRI paroxetine 20 mg/day for 8 weeks was only effective on depressive symptoms (anamnesis data), with no improvement in OCD symptoms. The antipsychotic risperidone was initiated with 3 mg/day of risperidone, which resulted in a major improvement, with more than a 50% decrease in YBOCS score after 1 week (subclinical: 7 points on YBOCS).
At this point, he first mentioned “recreational gambling” (going every other day to bet on football matches). After 8 weeks of continuous combination of risperidone and paroxetine, we saw a remission of BDD, with a YBOCS BDD score of 15. Coincidentally, the pathological gambling symptoms emerged after resolution of OCD and BDD, when DSM-IV PGD was diagnosed, with an initial score on of 35 on the GSAS (severe PGD).10 Furthermore, his mother complained about his multiple aggressive requests for money in order to bet. Therefore, Mr. N was started on memantine 20 mg/day. After 8 weeks of memantine treatment, we noted a more-than-50% reduction on the GSAS (mild disorder score: 10), with more control over his thoughts about gambling, less anticipatory tension and excitation, and no personal trouble and aggressive acts toward his mother. After 12 weeks of memantine treatment, the same GSAS score was maintained. Placebo-controlled trials are needed to confirm our findings. We also suggest that higher doses of memantine might prove to be more effective than those administered in dementia and in our case study.
1. : The case for OCD spectrum, in Concepts and Controversies in Obsessive-Compulsive Disorder. Edited by Abramowitz JSHouts AC. New York, Springer, 2005, pp 95–118Crossref, Google Scholar
2. : Obsessive-compulsive disorder versus body dysmorphic disorder: a comparison study of two possible related disorders. Depress Anx 2007; 24:399–409Crossref, Medline, Google Scholar
3. : Pharmacologic treatment of body dysmorphic disorder. Primary Psychiatry 2006; pp 61–69Google Scholar
4. : Epidemiological and clinical updates on impulse-control disorders. Eur Arch Psychiatry Clin Neurosci 2006; 256:464–475Crossref, Medline, Google Scholar
5. : Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genom 2008; 2:62–75Crossref, Google Scholar
6. : N-acetyl cysteine: a glutamate-modulating agent in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62:652–657Crossref, Medline, Google Scholar
7. : Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 1991; 198(2–3):215–217Crossref, Medline, Google Scholar
8. : A 1H-MR spectroscopy study of changes in glutamate and glutamine (Glx) concentrations in frontal spectra after administration of memantine. Cerebral Cortex 2010; 20:798–803Crossref, Medline, Google Scholar
9. : A single-blinded case–control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010; 30:34–39Crossref, Medline, Google Scholar
10. : The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res 2009; 31:76–84Google Scholar